Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer - Telli, M L; Hellyer, J; Audeh, W (Breast Cancer Res Treat, 2018)